Nonclinical precedent Request an invite
Species
Cynomolgus monkey only
“The toxicology program was carried out in cynomolgus monkeys, as it was demonstrated that the cynomolgus monkey and human have relevant HER2 sequence homology and affinity.”
✓ VerifiedEMA assessment report, p. 34Source ↗
Why that species
Similar HER2 ECD affinity human 0.74 nM vs monkey 0.47 nM; weaker for dog, no binding in rodents
“It was demonstrated that zanidatamab binds with similar affinity to human and cynomolgus monkey HER2 ECD (Kd = 0.74 and 0.47 nM, respectively), while the affinity for dog was lower (Kd = 4.07 nM) and no affinity was demonstrated for rodents”
✓ VerifiedEMA assessment report, p. 34Source ↗
Surrogate molecule
No surrogate; clinical molecule tested in cynomolgus monkey
“The cynomolgus monkey is considered a suitable species for characterizing the PK of zanidatamab as it binds both human and monkey HER2 molecules with similar subnanomolar affinity.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Species: general tox
Cynomolgus monkey only
“The cynomolgus monkey was selected as the most relevant species for toxicology testing based on considerations of sequence homology and affinity binding to HER2.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Species: DART
Not conducted; HER2 antibody class embryo-fetal toxicity (weight of evidence)
“Consequently, the conduct of de novo developmental and reproductive toxicity (DART) studies is not warranted for zanidatamab.”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Species: carcinogenicity
Not conducted (ICH S9)
“No carcinogenicity studies have been conducted with zanidatamab.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗
Surrogate used in
No surrogate used; clinical molecule tested in cynomolgus monkey
“The toxicology program was carried out in cynomolgus monkeys, as it was demonstrated that the cynomolgus monkey and human have relevant HER2 sequence homology and affinity.”
✓ VerifiedEMA assessment report, p. 34Source ↗

Same question, other multispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Cynomolgus monkey only

Blincyto

blinatumomab · CD19 x CD3
Chimpanzee (only relevant species, limited non-terminal studies) plus mouse with murine surrogate

Columvi

glofitamab · CD20 x CD3
Cynomolgus monkey only

Elrexfio

elranatamab · BCMA x CD3
Cynomolgus monkey only

Epkinly

epcoritamab · CD20 x CD3
Cynomolgus monkey only

Hemlibra

emicizumab · FIXa x FX
Cynomolgus monkey only

Imdelltra

tarlatamab · DLL3 x CD3
Cynomolgus monkey (pivotal); mouse surrogate muS757 for EFD and 1-month study

Kimmtrak

tebentafusp · CD3 x gp100 (TCR fusion)
No relevant species; in vitro human cell/tissue assays only

Korjuny

catumaxomab · EpCAM x CD3
No relevant species; limited single-dose mouse, rat, one cynomolgus; BiLu mouse surrogate

Lunsumio

mosunetuzumab · CD20 x CD3
Cynomolgus monkey only

Lynozyfic

linvoseltamab · BCMA x CD3
Cynomolgus monkey only

Ordspono

odronextamab · CD20 x CD3
Cynomolgus monkey only

Removab

catumaxomab · EpCAM x CD3
No relevant species; in vitro human cells plus mouse surrogate (BiLu); limited single-dose rodent/monkey

Rybrevant

amivantamab · EGFR x MET
Cynomolgus monkey only

Talvey

talquetamab · GPRC5D x CD3
Cynomolgus monkey only (tool molecule for pivotal tox); no rodent tox

Tecvayli

teclistamab · BCMA x CD3
Cynomolgus monkey only (rabbit used for SC local tolerance only)

Vabysmo

faricimab · VEGF-A x Ang-2
Cynomolgus monkey only for pivotal tox (rabbit dropped after early studies)

Summary across all 18 multispecifics →